Weekly administration of alendronate: Rationale and plan for clinical assessment
- 1 January 2000
- journal article
- review article
- Published by Elsevier in Clinical Therapeutics
- Vol. 22 (1) , 15-28
- https://doi.org/10.1016/s0149-2918(00)87974-6
Abstract
No abstract availableKeywords
This publication has 38 references indexed in Scilit:
- Skeletal Benefits of Two Years of Alendronate Treatment Are Similar for Early Postmenopausal Asian and Caucasian WomenOsteoporosis International, 1999
- Multinational, Placebo-Controlled, Randomized Trial of the Effects of Alendronate on Bone Density and Fracture Risk in Postmenopausal Women with Low Bone Mass: Results of the FOSIT StudyOsteoporosis International, 1999
- Effect of Alendronate on Risk of Fracture in Women With Low Bone Density but Without Vertebral FracturesResults From the Fracture Intervention TrialJAMA, 1998
- Alendronate for the Prevention and Treatment of Glucocorticoid-Induced OsteoporosisNew England Journal of Medicine, 1998
- Prevention of Bone Loss with Alendronate in Postmenopausal Women under 60 Years of AgeNew England Journal of Medicine, 1998
- Alendronate Prevents Postmenopausal Bone Loss in Women without Osteoporosis: A Double-Blind, Randomized, Controlled TrialAnnals of Internal Medicine, 1998
- Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fracturesThe Lancet, 1996
- Biochemical and radiologic improvement in Paget's disease of bone treated with alendronate: A randomized, placebo-controlled trialThe American Journal of Medicine, 1996
- Comparative study of alendronate versus etidronate for the treatment of Paget's disease of boneJournal of Clinical Endocrinology & Metabolism, 1996
- Effect of Oral Alendronate on Bone Mineral Density and the Incidence of Fractures in Postmenopausal OsteoporosisNew England Journal of Medicine, 1995